Potential benefits of rho-kinase inhibition in arterial hypertension

Current Hypertension Reports

Volumn 15, Issue 5, 2013, Pages 506-513

  Grisk, Olaf ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Angiotensin II; Arteries; Blood pressure; Blood vessels; Brain stem; Calciumchannels; Diabetes; Endothelium; Fasudil; Fibrosis; Genetics; Glomerular filtration rate; GTP binding proteins; Hypertension; Kidney; Kidney diseases; Mice; Pharmacokinetics; Protein kinases; Rats; Rho associated kinases; Signal transduction; Sympathetic nervous system; Therapeutics; Vascular smooth muscle

Indexed keywords

ISOENZYME; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO KINASE INHIBITOR;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL RESEARCH; EXPERIMENTAL ANIMAL; EXPERIMENTAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MORTALITY; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN EXPRESSION; VASCULAR CAPACITY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84893655003     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0373-0     Document Type: Article

References (86)

1. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens. 2006;24(3):413-22.
2. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-92. doi:10.1097/01. hjh.0000084751.37215.d2.
3. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens. 2006;24(3):423-30. doi:10.1097/01.hjh. 0000209973.67746.f0.
4. Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput. 2008;46(5):461-7. doi:10.1007/s11517-008-0305-3.
5. Guyton AC. Blood pressure control-special role of the kidneys and body fluids. Science. 1991;252(5014):1813-6.
6. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1001-18. doi:10.1152/ajpregu.90960.2008.
7. Chalmers J, Arima H, Harrap S, Touyz RM, Park JB. Global survey of current practice inmanagement of hypertension as reported by societies affiliated with the international society of hypertension. J Hypertens. 2013;31(5):1043-8. doi:10.1097/HJH.0b013e32835f7eef.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.
9. Fletcher RD, Amdur RL, Kolodner R, McManus C, Jones R, Faselis C, et al. Blood pressure control among US veterans: a largemultiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125(20):2462-8. doi:10. 1161/CIRCULATIONAHA.111.029983.
10. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105-14. doi:10.1161/CIRCULATIONAHA.112.096156.
11. Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol. 2007;100(3 A):3J-9J. doi:10.1016/j.amjcard. 2007.05.008.
12. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26. doi:10.1161/CIRCULATIONAHA.108.189141.
13. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. doi:10.1161/CIRCULATIONAHA.111.068064.
14. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50(1):17-24. doi:10.1097/FJC.0b013e318070d1bd.
15. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci: CMLS. 2010;67(2):171-7. doi:10.1007/s00018-009-0189-x. Provides an overview on isoenzyme selectivity of ROCK inhibitors.
16. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98(3):322-34. doi:10.1161/01. RES.0000201960.04223.3c.
17. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta. 2010;1802(12):1276-84. doi:10.1016/j.bbadis.2010.05.002. Provides a recent comprehensive overview on the regulation of ROCK activity, ROCK substrates and the role of ROCKs in vascular biology.
18. Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci: CMLS. 2010;67(22):3823-36. doi:10.1007/s00018- 010-0460-1.
19. Duess JW, Fujiwara N, Corcionivoschi N, Puri P, Thompson J. ROCK inhibitor (Y-27632) disrupts somitogenesis in chick embryos. Pediatr Surg Int. 2013;29(1):13-8. doi:10.1007/s00383-012-3202-7.
20. Phillips HM, Papoutsi T, Soenen H, Ybot-Gonzalez P, Henderson DJ, Chaudhry B. Neural crest cell survival is dependent on Rho kinase and is required for development of the mid face in mouse embryos. PLoS One. 2012;7(5):e37685. doi:10.1371/journal.pone.0037685.
21. Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T, et al. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res. 2008;29(3):155-61.
22. Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Li QQ, et al. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat. 2011;126(3):555-63. doi:10.1007/s10549-010- 0955-3.
23. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol. 2003;23(14):5043-55.
24. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168(6):941-53. doi:10. 1083/jcb.200411179.
25. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990-4. doi:10. 1038/40187.
26. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension. 2009;54(3):676-83. doi:10.1161/HYPERTENSIONAHA.109. 134353.
27. Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol. 2007;47(1):19-25. doi:10.1177/0091270006293767.
28. Chen YT, Bannister TD, Weiser A, Griffin E, Lin L, Ruiz C, et al. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg Med Chem Lett. 2008;18(24):6406-9. doi:10.1016/j.bmcl.2008.10.080.
29. Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008;51(21):6631-4. doi:10. 1021/jm8005096.
30. Sessions EH, Yin Y, Bannister TD, Weiser A, Griffin E, Pocas J, et al. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg Med Chem Lett. 2008;18(24):6390-3. doi:10.1016/j.bmcl. 2008. 10.095.
31. Shahin R, Alqtaishat S, Taha MO. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors. J Comput Aided Mol Des. 2012;26(2):249-66. doi:10.1007/s10822-011-9509-y.
32. Yin Y, Lin L, Ruiz C, Khan S, Cameron MD, Grant W, et al. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. J Med Chem. 2013;56(9):3568-81. doi:10.1021/jm400062r.
33. Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, et al. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol. 2007;152(7):1070-80. doi:10.1038/sj.bjp. 0707484.
34. Prakash J, De Borst MH, Lacombe M, Opdam F, Klok PA, Van Goor H, et al. Inhibition of renal rho kinase attenuates ischemia/reperfusioninduced injury. J Am Soc Nephrol: JASN. 2008;19(11):2086-97. doi:10.1681/ASN.2007070794.
35. Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol. 2012;52(1):83-92. doi:10.1016/j.yjmcc.2011.09.014.
36. Ying Z, Giachini FR, Tostes RC, Webb RC. Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation. Cardiovasc Res. 2009;83(1):155-62. doi:10.1093/cvr/cvp084.
37. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, et al. Nonsteroidal antiinflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science. 2003;302(5648):1215-7. doi:10.1126/science.1090154.
38. Fu Q, Hue J, Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci: Off J Soc Neurosci. 2007;27(15):4154-64. doi:10.1523/JNEUROSCI.4353-06.2007.
39. Schluter T, Steinbach AC, Steffen A, Rettig R, Grisk O. Apocynininduced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition. Cardiovasc Res. 2008;80(2):271-9. doi:10.1093/cvr/cvn185.
40. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res. 2004;95(5):e45-55. doi:10.1161/01. RES.0000142313.68389.92.
41. Nochioka K, Tanaka S, Miura M, Do Zhulanqiqige E, Fukumoto Y, Shiba N, et al. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J. 2012;76(8):2023-30.
42. Ghisdal P, Vandenberg G, Morel N. Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries. J Physiol. 2003;551(Pt 3):855-67. doi:10.1113/jphysiol.2003.047050.
43. Sakurada S, Takuwa N, Sugimoto N, Wang Y, Seto M, Sasaki Y, et al. Ca2+-dependent activation of Rho and Rho kinase in membrane depolarization- induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res. 2003;93(6):548-56. doi:10. 1161/01. RES.0000090998.08629.60.
44. 2+channels: newmechanism for depolarization-evoked mammalian arterial contraction. Circ Res. 2011;108(11):1348-57. doi:10.1161/CIRCRESAHA.111.240127.
45. Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Fujimura N, et al. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens. 2011;29(2):373-9. doi:10. 1097/HJH.0b013e328340902d. A clinical study that provides data indicating that CCBs inhibit ROCK activity in hypertensive patients suggesting that CCB actions are partly due to indirect ROCK inhibition.
46. Althoff TF, Juarez JA, Troidl K, Tang C, Wang S, Wirth A, et al. Procontractile G protein-mediated signaling pathways antagonistically regulate smooth muscle differentiation in vascular remodeling. J Exp Med. 2012;209(12):2277-90. doi:10.1084/jem.20120350. This study shows that signaling via the G12/13 pathway which activates ROCK is essential for maitaining a differentiated phenotype in vascular smooth muscle cells and reduces the suceptibility to vascular injury. This is achieved by using several smooth muscle cell-specific knock out mouse models.
47. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, et al. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res. 2009;104(4):531-40. doi:10.1161/CIRCRESAHA.108.188524.
48. Lin T, Zeng L, Liu Y, De Fea K, Schwartz MA, Chien S, et al. Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res. 2003;92(12):1296-304. doi:10.1161/01. RES.0000078780.65824.8B.
49. Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24(9):3186-95. doi:10. 1096/fj.09-145102. ROCK II is identified as an essetial part of VEGFinduced angiogenesis using hemizygous ROCK-deficient mice.
50. Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Investig. 2010;120(1):315-30. doi:10.1172/JCI38356.
51. Dhaliwal JS, Casey DB, Greco AJ, Badejo Jr AM, Gallen TB, Murthy SN, et al. Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1306-13. doi:10.1152/ajplung.00189.2007.
52. Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, et al. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010;299(1):H184-92. doi:10.1152/ajpheart.00181.2009.
53. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38(6):1307-10.
54. Hata T, Goto C, Soga J, Hidaka T, Fujii Y, Idei N, et al. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011;214(1):117-21. doi:10.1016/j. atherosclerosis.2010.10.005.
55. Smith CJ, Santhanam L, Alexander LM. Rho-Kinase activity and cutaneous vasoconstriction is upregulated in essential hypertensive humans. Microvasc Res. 2013;87:58-64. doi:10.1016/j.mvr.2013.02.005. The study provides direct evidence for RhoA/ROCK activation in the microvasculature of humans with high blood pressure.
56. Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis. 2009;207(2):567-72. doi:10. 1016/j.atherosclerosis. 2009.05.025.
57. Seasholtz TM, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, et al. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension. 2006;47(5):937-47. doi:10.1161/01. HYP.0000217364.45622.f0.
58. Zhao Q, Wang L, Yang W, Chen S, Huang J, Fan Z, et al. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenet Genomics. 2008;18(6):459-66. doi:10.1097/FPC. 0b013e3282f97fb2.
59. Rankinen T, Church T, Rice T, Markward N, Blair SN, Bouchard C. A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. Hypertens Res: Off J Jpn Soc Hypertens. 2008;31(8):1651-7. doi:10.1291/hypres.31.1651.
60. Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N, et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol: JASN. 2003;14(1):37-45.
61. Roos MH, Van Rodijnen WF, Van Lambalgen AA, Ter Wee PM, Tangelder GJ. Renal microvascular constriction to membrane depolarization and other stimuli: pivotal role for rho-kinase. Pflugers Archiv: Eur J Physiol. 2006;452(4):471-7. doi:10.1007/s00424-006-0053-x.
62. Inscho EW, Cook AK, Webb RC, Jin LM. Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Ren Physiol. 2009;296(3):F590-7. doi:10.1152/ajprenal.90703.2008.
63. Grisk O, Schluter T, Reimer N, Zimmermann U, Katsari E, Plettenburg O, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012;30(5):980-9. doi:10.1097/HJH.0b013e328351d459.
64. Liu Y, Echtermeyer F, Thilo F, Theilmeier G, Schmidt A, Schulein R, et al. The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via RhoA/Rho-associated protein kinase signaling. Arterioscler Thromb Vasc Biol. 2012;32(2):378-85. doi:10.1161/ATVBAHA.111.241018.
65. Eisen R, Walid S, Ratcliffe DR, Ojakian GK. Regulation of epithelial tubule formation by Rho family GTPases. Am J Physiol Cell Physiol. 2006;290(5):C1297-309. doi:10.1152/ajpcell.00287.2005.
66. Szaszi K, Sirokmany G, Di Ciano-Oliveira C, Rotstein OD, Kapus A. Depolarization induces Rho-Rho kinase-mediated myosin light chain phosphorylation in kidney tubular cells. Am J Physiol Cell Physiol. 2005;289(3):C673-85. doi:10.1152/ajpcell.00481.2004.
67. Ramseyer VD, Hong NJ, Garvin JL. Tumor necrosis factor alpha decreases nitric oxide synthase type 3 expression primarily via Rho/Rho kinase in the thick ascending limb. Hypertension. 2012;59(6):1145-50. doi:10.1161/ HYPERTENSIONAHA.111.189761. The study shows that RhoA/ROCK mediate downregulation of eNOS (NOS3) in isolated rat thick ascending limb suggesting that this pathway could be involved in renal tubular sodium retention.
68. Li W, Zhang Y, Bouley R, Chen Y, Matsuzaki T, Nunes P, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Ren Physiol. 2011;301(2):F309-18. doi:10.1152/ajprenal.00001.2011.
69. Grisk O, Packebusch M, Steinbach AC, Schluter T, Kopp UC, Rettig R. Endothelin-1-induced activation of rat renal pelvic contractions depends on cyclooxygenase-1 and Rho kinase. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1602-9. doi:10.1152/ajpregu.00452.2010.
70. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, et al. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens. 2007;25(5):1053-63. doi:10.1097/HJH.0b013e3280825440.
71. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension. 2006;47(6):1075-83. doi:10.1161/01. HYP.0000221605.94532.71.
72. Williams JM, Johnson AC, Stelloh C, Dreisbach AW, Franceschini N, Regner KR, et al. Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat. Hypertension. 2012;60(5):1157-68. doi:10.1161/ HYPERTENSIONAHA.112.199240. Using congenic rat lines the authors identify a Rho guanine nucleotide exchange factor gene of Dahl-S rats as cause of increased susceptibility to hypertensive renal disease.
73. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005;45(4):538-44. doi:10. 1161/01. HYP.0000157408.43807.5a.
74. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens. 2008;26(9):1837-48. doi:10.1097/HJH.0b013e328305086c.
75. Komers R, Oyama TT, Beard DR, Anderson S. Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats. Br J Pharmacol. 2011;162(1):163-74. doi:10.1111/j. 1476-5381.2010.01031.x.
76. Mustafa S, Vasudevan H, Yuen VG, McNeill JH. Renal expression of arachidonic acid metabolizing enzymes and RhoA/Rho kinases in fructose insulin resistant hypertensive rats. Mol Cell Biochem. 2010;333(1-2):203-9. doi:10.1007/s11010-009-0220-4.
77. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2 (5). doi:10.1136/bmjopen-2012-001007.
78. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther. 2013;139(1):51-9. doi:10.1016/j.pharmthera.2013.04.003.
79. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619-26. doi:10.1161/HYPERTENSIONAHA. 109. 140665.
80. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82. doi:10. 1161/CIRCULATIONAHA.112.130880.
81. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res. 2003;92(12):1337-43. doi:10.1161/01. RES.0000079941.59846. D4.
82. Ito K, Hirooka Y, Sagara Y, Kimura Y, Kaibuchi K, Shimokawa H, et al. Inhibition of Rho-kinase in the brainstem augments baroreflex control of heart rate in rats. Hypertension. 2004;44(4):478-83. doi:10.1161/01. HYP.0000143120.24612.68.
83. Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway viaAT1 receptors. J Hypertens. 2007;25(2):399-406. doi:10.1097/HJH.0b013e328010b87f.
84. Kumai T, Takeba Y, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, et al. Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. Life Sci. 2007;81(15):1193-8. doi:10.1016/j.lfs.2007.08.008.
85. Thoenen H, Mueller RA, Axelrod J. Trans-synaptic induction of adrenal tyrosine hydroxylase. J Pharmacol Exp Ther. 1969;169(2):249-54.
86. Satoh N, Toyohira Y, Itoh H, Zhang H, Ueno S, Tsutsui M, et al. Stimulation of norepinephrine transporter function by fasudil, a Rho kinase inhibitor, in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(9):921-31. doi:10.1007/s00210-012-0773-8.